These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 27561302)

  • 1. B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.
    Thomas PJ; Xu R; Martin PT
    Am J Pathol; 2016 Sep; 186(9):2429-48. PubMed ID: 27561302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice.
    Xu R; DeVries S; Camboni M; Martin PT
    Am J Pathol; 2009 Jul; 175(1):235-47. PubMed ID: 19498002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.
    Xu R; Singhal N; Serinagaoglu Y; Chandrasekharan K; Joshi M; Bauer JA; Janssen PM; Martin PT
    Am J Pathol; 2015 Oct; 185(10):2668-84. PubMed ID: 26435413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates.
    Chicoine LG; Rodino-Klapac LR; Shao G; Xu R; Bremer WG; Camboni M; Golden B; Montgomery CL; Shontz K; Heller KN; Griffin DA; Lewis S; Coley BD; Walker CM; Clark KR; Sahenk Z; Mendell JR; Martin PT
    Mol Ther; 2014 Apr; 22(4):713-24. PubMed ID: 24145553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength.
    Martin PT; Zygmunt DA; Ashbrook A; Hamilton S; Packer D; Birch SM; Bettis AK; Balog-Alvarez CJ; Guo LJ; Nghiem PP; Kornegay JN
    PLoS One; 2021; 16(3):e0248721. PubMed ID: 33770101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy.
    Yu Q; Morales M; Li N; Fritz AG; Ruobing R; Blaeser A; Francois E; Lu QL; Nagaraju K; Spurney CF
    Skelet Muscle; 2018 Apr; 8(1):13. PubMed ID: 29625576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.
    Xu R; Chandrasekharan K; Yoon JH; Camboni M; Martin PT
    Am J Pathol; 2007 Jul; 171(1):181-99. PubMed ID: 17591965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart.
    Xu R; Jia Y; Zygmunt DA; Martin PT
    Mol Ther; 2019 Mar; 27(3):636-649. PubMed ID: 30711447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions.
    Xu L; Lu PJ; Wang CH; Keramaris E; Qiao C; Xiao B; Blake DJ; Xiao X; Lu QL
    Mol Ther; 2013 Oct; 21(10):1832-40. PubMed ID: 23817215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation.
    Alhamidi M; Brox V; Stensland E; Liset M; Lindal S; Nilssen Ø
    Neuromuscul Disord; 2017 Jul; 27(7):619-626. PubMed ID: 28479227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexually dimorphic skeletal muscle and cardiac dysfunction in a mouse model of limb girdle muscular dystrophy 2i.
    Maricelli JW; Kagel DR; Bishaw YM; Nelson OL; Lin DC; Rodgers BD
    J Appl Physiol (1985); 2017 Nov; 123(5):1126-1138. PubMed ID: 28663375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-Associated Virus-Mediated Mini-Agrin Delivery Is Unable to Rescue Disease Phenotype in a Mouse Model of Limb Girdle Muscular Dystrophy Type 2I.
    Vannoy CH; Zhou H; Qiao C; Xiao X; Bang AG; Lu QL
    Am J Pathol; 2017 Feb; 187(2):431-440. PubMed ID: 28107841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.
    Wu B; Shah SN; Lu P; Richardson SM; Bollinger LE; Blaeser A; Madden KL; Sun Y; Luckie TM; Cox MD; Sparks S; Harper AD; Lu QL
    Am J Pathol; 2016 Jun; 186(6):1635-48. PubMed ID: 27109613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery.
    Qiao C; Wang CH; Zhao C; Lu P; Awano H; Xiao B; Li J; Yuan Z; Dai Y; Martin CB; Li J; Lu Q; Xiao X
    Mol Ther; 2014 Nov; 22(11):1890-9. PubMed ID: 25048216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice.
    Martin PT; Xu R; Rodino-Klapac LR; Oglesbay E; Camboni M; Montgomery CL; Shontz K; Chicoine LG; Clark KR; Sahenk Z; Mendell JR; Janssen PM
    Am J Physiol Cell Physiol; 2009 Mar; 296(3):C476-88. PubMed ID: 19109526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
    Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
    Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies.
    Chan YM; Keramaris-Vrantsis E; Lidov HG; Norton JH; Zinchenko N; Gruber HE; Thresher R; Blake DJ; Ashar J; Rosenfeld J; Lu QL
    Hum Mol Genet; 2010 Oct; 19(20):3995-4006. PubMed ID: 20675713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.
    Serafini PR; Feyder MJ; Hightower RM; Garcia-Perez D; Vieira NM; Lek A; Gibbs DE; Moukha-Chafiq O; Augelli-Szafran CE; Kawahara G; Widrick JJ; Kunkel LM; Alexander MS
    JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I.
    Boito CA; Melacini P; Vianello A; Prandini P; Gavassini BF; Bagattin A; Siciliano G; Angelini C; Pegoraro E
    Arch Neurol; 2005 Dec; 62(12):1894-9. PubMed ID: 16344347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient engraftment of pluripotent stem cell-derived myogenic progenitors in a novel immunodeficient mouse model of limb girdle muscular dystrophy 2I.
    Azzag K; Ortiz-Cordero C; Oliveira NAJ; Magli A; Selvaraj S; Tungtur S; Upchurch W; Iaizzo PA; Lu QL; Perlingeiro RCR
    Skelet Muscle; 2020 Apr; 10(1):10. PubMed ID: 32321586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.